Which of the following new drug is indicated in managing SIADH , non - * peptide and competitive antagonist of ADH 's water sparing effects in the collecting ducts of nephron?
Correct Answer: D
Rationale: The correct answer is D: Conivaptan. Conivaptan is a non-peptide competitive antagonist of ADH, specifically targeting the V2 receptors in the collecting ducts of the nephron. This mechanism of action inhibits ADH's water-sparing effects, making it an effective treatment for SIADH.
A: Mannitol is an osmotic diuretic used for conditions like cerebral edema and acute kidney injury, not specifically for SIADH.
B: Bumetanide is a loop diuretic used for conditions like heart failure and hypertension, not for managing SIADH.
C: Spironolactone is a potassium-sparing diuretic used for conditions like heart failure and hypertension, not for treating SIADH.
In summary, Conivaptan is the correct choice for managing SIADH due to its specific mechanism of action as a competitive antagonist of ADH in the collecting ducts, while the other options are